Month: August 2021
Excerpt from the Press Release: WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT7455…
Read More
Excerpt from the Press Release: Moderna Inc. plans to double enrollment in a trial of its Covid vaccine in children under age 12, following a request from U.S. regulators to collect additional safety data. Moderna’s study will enroll an estimated 13,275 participants ages 6 months up to 12 years old, according to a listing on the clinicaltrials.gov website. In a…
Read More
Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–Despite representing roughly 12% of the U.S. adult population, in biopharma, Black professionals account for just 7% of the total workforce and 3% of executive teams. Today, in an initiative designed to increase access to and awareness of the biopharma industry among Black talent and build a diverse talent…
Read More
Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a subsidiary of Otsuka Pharmaceutical Co., Ltd., announces that it has been awarded a grant for up to $17.8 million from the Bill & Melinda Gates Foundation. This will enable Otsuka to advance clinical trials of its investigational compound OPC-167832, in…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first TP53-mutated acute myeloid leukemia (AML) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune…
Read More
Excerpt from the Press Release: CARLSBAD, Calif., Aug. 9, 2021 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, today announced it has updated its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to detect the Delta and Lambda strains. First launched in March 2021, the research panel features a customizable menu of verified real-time PCR assays for identification of…
Read More
Excerpt from the Press Release: FREMONT, Calif., Aug. 5, 2021 /PRNewswire/ — Verseon today announced that VE-4840 will advance as the company’s primary diabetic retinopathy (DR) development candidate after it passed preliminary toxicology studies. Orally administered VE-4840 has also demonstrated significant reduction of diabetes-induced retinal vascular permeability (RVP) in vivo. These results, along with its excellent oral pharmacokinetics…
Read More
Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, Aug. 5, 2021 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, and Eli Lilly and Company (NYSE: LLY) today announced new and updated data from the ORIENT-11…
Read More
Excerpt from the Press Release: BEVERLY, Mass.–(BUSINESS WIRE)–Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate. Fifty-two volunteers will receive either one- or two-dose regimens as part of the Phase II…
Read More
Excerpt from the Press Release: Digital healthcare adoption has accelerated since the onset of the pandemic. In the first half of 2021, approximately $14.7B was invested in digital healthcare in the US, surpassing the total amount invested in 2020 (~$14B). Building on a world-class talent pool, AI startups are also booming in Canada with ~$1.4B raised in the first 6…
Read More